VitusCare – A vital change in Dialysis Care
In India, access to quality dialysis remains a critical healthcare gap, especially in smaller cities and rural areas. With around 2.2 lakh new end-stage kidney disease cases every year, the demand for dialysis far outpaces availability.
This shortage leaves countless patients traveling long distances for essential care. Recognizing this need, VitusCare Medlife, founded in 2017, has focused on bringing affordable dialysis closer to home for people in underserved regions.
VitusCare operates 35 centers across North India, primarily in Tier 2 and Tier 3 cities, providing more than 15,000 dialysis sessions each month.
Most of their centers are set up within existing hospitals, ensuring that patients can access quality care without the need to travel hundreds of kilometers.
The founders, Prabhat Shrivastava, Dr. Saurabh Pokhariyal, and Pankaj Tandon, developed a model that enables strict quality control and oversight, with a central operations team based in Gurgaon managing the standards across all centers.
India’s dialysis needs are further complicated by affordability issues. Though the government’s Pradhan Mantri National Dialysis Programme (PMNDP) offers free dialysis through select centers, this doesn’t cover everyone.
VitusCare addresses this by offering free treatment under the Ayushman Bharat scheme, supporting lower-income patients.
The founders also emphasize that missed dialysis sessions can be life-threatening, as waste builds up in the body, causing serious complications.
While kidney transplants remain an option for some, they are costly and limited by a lack of available donors, making dialysis the main lifeline for most patients.
Recently, VitusCare secured Series A funding, which will help it expand its services. For Prabhat and his co-founders, the goal remains clear: improving quality of life for kidney patients who would otherwise struggle to access regular, reliable care.
Image Credit: Vituscare Website Screenshot
Image Reference: https://www.vituscare.com/
Leave a Reply